News
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with
deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. The
Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test in Italy
SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test for identifying high risk early-stage breast
Ultrathin Graphene Brain Implant Was Just Tested in a Person
A Spanish biotech company sees the carbon material as a way to power the brain-computer interfaces of the future. Read more
Peptomyc Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer
Peptomyc S.L., a company developing foundational mini-protein therapeutics for the treatment of cancer, announces today that the Company has been issued a patent by the
